MedPath

HEALTH RESEARCH, INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab

Phase 4
Conditions
Osteoporosis
Interventions
Drug: Experimental Cyclic Regimen
Drug: Standard Clinical Practice Regimen
First Posted Date
2014-05-06
Last Posted Date
2017-08-31
Lead Sponsor
Health Research, Inc.
Target Recruit Count
60
Registration Number
NCT02130973
Locations
🇺🇸

Helen Hayes Hospital, West Haverstraw, New York, United States

Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur

Not Applicable
Completed
Conditions
Osteoporosis
Interventions
Other: placebo
Drug: Teriparatide
First Posted Date
2011-03-07
Last Posted Date
2016-11-23
Lead Sponsor
Health Research, Inc.
Target Recruit Count
40
Registration Number
NCT01309399
Locations
🇺🇸

Helen Hayes Hospital, West Haverstraw, New York, United States

© Copyright 2025. All Rights Reserved by MedPath